Q3 Earnings Estimate for OKYO Pharma Issued By HC Wainwright

Key Points

• HC Wainwright initiated Q3 2027 earnings estimates for OKYO Pharma at ($0.03) per share and kept a Buy rating with a $5.00 price target.
• The stock has mixed analyst sentiment overall: three Buy ratings, one Hold, and one Sell, with a consensus Hold and an average price target of $5.67.
• OKYO Pharma shares were down 8.3% and traded at $1.55, well below the analyst price targets; the company remains a clinical-stage biopharmaceutical firm with lead candidate OK-101 in Phase 2 for diabetic kidney disease.

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Free Report) - Investment analysts at HC Wainwright issued their Q3 2027 earnings estimates for OKYO Pharma in a research report issued to clients and investors on Monday, July 13th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.03) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for OKYO Pharma's current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for OKYO Pharma's Q4 2027 earnings at ($0.03) EPS, FY2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.03) EPS, Q2 2028 earnings at ($0.04) EPS, Q3 2028 earnings at ($0.04) EPS, Q4 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.15) EPS.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $5.67.

OKYO Pharma Trading Down 8.3%

Shares of OKYO Pharma stock opened at $1.55 on Tuesday. The business's 50 day simple moving average is $1.61 and its 200-day simple moving average is $1.77. OKYO Pharma has a twelve month low of $1.42 and a twelve month high of $3.35.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new position in OKYO Pharma in the 3rd quarter worth about $31,000. XTX Topco Ltd purchased a new stake in OKYO Pharma during the fourth quarter valued at about $36,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company's stock worth $286,000 after buying an additional 96,800 shares during the period. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.